Citrus Therapeutics to Present CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD) at Ophthalmology Innovation Summit XII
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Nov. 21, 2022 - PRLog -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal)
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email email@example.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Dr. David Almeida, firstname.lastname@example.org